4SC AG / Key word(s): Capital Increase
23.02.2011 17:45
Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Planegg-Martinsried, Germany, 23 February, 2011 - The management board of
4SC AG (Frankfurt, Prime Standard: VSC), a drug discovery and development
company focused on autoimmune and cancer indications, decided today with
the supervisory board's consent to make partial use of the authorised
capital to increase the Company's share capital from 38,502,739 shares to
up to 42,353,011 shares by issuing up to 3,850,272 new, no-par value bearer
shares, each with a notional interest of EUR 1.00 in the share capital. The
new shares will be offered to institutional investors as part of an
accelerated book-building process, excluding the subscription rights of the
existing shareholders.
Kempen & Co. is acting as Lead Manager and Donner & Reuschel Privatbank is
acting as the Listing Agent for the transaction.
- End of Ad-hoc Notification -
About 4SC
4SC AG (ISIN DE0005753818) is a drug discovery and development company
focused on autoimmune and cancer indications. Vidofludimus (4SC-101), a
small molecule, is currently in Phase II development in rheumatoid
arthritis and inflammatory bowel disease (IBD), for which positive results
from a Phase IIa study were recently reported. The company's lead oncology
compound, resminostat (4SC-201), a pan-histone deacetylase (HDAC)
inhibitor, is in Phase II trials in hepatocellular carcinoma, Hodgkin's
lymphoma and KRAS-mutant colorectal cancer. Two further oncology compounds,
4SC-203 and 4SC-205, are in Phase I studies. 4SC develops drug candidates
until proof-of-concept in order to generate value creating partnerships
with the pharmaceutical industry in return for advance and milestone
payments as well as royalties.
Founded in 1997, 4SC has 94 employees and has been listed on the Prime
Standard of the Frankfurt Stock Exchange since December 2005.
For further information, please visit www.4sc.com.
Disclaimer
This publication may contain projections or estimates relating to plans and
objectives relating to future operations, products, or services, future
financial results or assumptions underlying or relating to any such
statements. These forward looking statements are subject
to risks and uncertainties, which cannot be foreseen and which are beyond
the control of 4SC AG. Many factors can cause actual results to differ
materially from any estimates expressed or implied by this publication. 4SC
AG has no obligation to periodically update or release any
revisions to the forward-looking statements contained in this publication
to
reflect events or circumstances after the date of this release.
This publication constitutes neither an offer to sell nor a solicitation to
buy securities of 4SC AG. The shares of 4SC AG may only be
offered or sold in the United States after
registration or without registration under an exemption from the
registration requirements of the U.S. Securities Act of 1933, as 4SC AG has
no obligation to periodically update or release any revisions to the
forward-looking statements contained in this release to
reflect events or circumstances after the date of this release. Shares have
not been and will not be registered under the Securities Act. 4SC AG
intends no public offering of the shares in the United States.
For more information please contact:
4SC AG
Yvonne Alexander, IR & PR
Tel.: +49 (0) 89 70 07 63 66
MC Services (Europe)
Raimund Gabriel
Tel.: +49 (0) 89 21 02 28 30
The Trout Group (USA)
Chad Rubin
Tel.: +1 646 378 2947
23.02.2011 DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: 4SC AG
Am Klopferspitz 19a
82152 Martinsried
Deutschland
Phone: +49 (0)89 7007 63-0
Fax: +49 (0)89 7007 63-29
E-mail: public@4sc.com
Internet: www.4sc.de
ISIN: DE0005753818
WKN: 575381
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Berlin, Düsseldorf, München, Stuttgart
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
DGAP-Adhoc: 4SC Announces Capital Increase
| Source: EQS Group AG